For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | - | - | - | 0 |
| Research and development | 70,000 | -824,319* | - | 423,277 |
| General and administrative | 728,509 | 2,383,382.5* | 527,902 | 919,488 |
| Asset impairment gain | - | -805,492* | - | 402,746 |
| Total operating expenses | 798,509 | 753,571.5 | 527,902 | 1,745,511 |
| Loss from operations | -798,509 | -753,571.5* | -527,902 | -1,745,511 |
| Interest expense, net | -2,129 | -43,879* | 8,116 | 4,866 |
| Inducement expense | - | - | - | 0 |
| Change in fair value of contingent consideration and derivative financial instruments | - | -5,207,782.5* | 47,280 | 698,073 |
| Loss before income taxes | - | -6,005,233 | -472,506 | -1,042,572 |
| Income tax benefit | - | - | - | 0 |
| Change in fair value of derivative financial instrumentswarrants | -10,153 | - | - | - |
| Net loss | -810,791 | -6,005,233 | -472,506 | -1,042,572 |
| Basic EPS | -0.07 | -1.137 | -0.04 | -0.09 |
| Diluted EPS | -0.07 | -1.137 | -0.04 | -0.09 |
| Basic Average Shares | 11,620,317 | 5,279,686 | 11,620,317 | 11,328,122 |
| Diluted Average Shares | 11,620,317 | 5,279,686 | 11,620,317 | 11,328,122 |
Hepion Pharmaceuticals, Inc. (CTRVP)
Hepion Pharmaceuticals, Inc. (CTRVP)